{
    "Results": [
        {
            "FileId": "34438_4",
            "Title": "<em>Glycemic</em> Control",
            "PremiumContentType": "off-label",
            "Headings": [
                {
                    "HeadingId": 4,
                    "Heading": "<em>Glycemic</em> Control in Phase 3 Trials",
                    "Content": [
                        "Change from baseline in various <em>glycemic</em> control parameters was a secondary endpoint in all of the SCALE",
                        "<em>Glycemic</em> Control in Phase 3 Trials of Saxenda® in patients WITHOUT type 2 diabetes.\n\n\t\t\t\t\n  \n    \n       ",
                        "<em>Glycemic</em> parameters in Phase 3 Trials of Saxenda® in patients WITH prediabetes or type 2 diabetes."
                    ]
                },
                {
                    "HeadingId": 1,
                    "Heading": "Summary",
                    "Content": [
                        "<em>Glycemic</em> status at baseline can be seen in  Table 1.",
                        "Saxenda® was associated with improvements in fasting and postprandial glycemia, as well as overall <em>glycemic</em>",
                        "and 268 (36%) out of 738 of placebo-treated patients had reverted from prediabetes to having normal <em>glycemic</em>"
                    ]
                },
                {
                    "HeadingId": 3,
                    "Heading": "Overview of the Phase 3 Clinical Development Program",
                    "Content": [
                        "with comorbidities or ≥30\n      ≥27 with comorbidities or ≥30\n      ≥27\n      ≥ 30\n    \n    \n      <em>Glycemic</em>"
                    ]
                }
            ]
        }
    ]
}